Li Ya, Yang Wei, Wu Xin, Gou Xiaohua
Ya Li, Pulmonary and Critical Care Medicine 2 Department, Baoding First Central Hospital, Baoding071000, Hebei, China.
Wei Yang, Pulmonary and Critical Care Medicine 2 Department, Baoding First Central Hospital, Baoding071000, Hebei, China.
Pak J Med Sci. 2022 Mar-Apr;38(4Part-II):922-927. doi: 10.12669/pjms.38.4.4835.
To investigate the clinical efficacy of budesonide suspension through bronchofiberscopic lavage in the treatment of refractory mycoplasma pneumoniae pneumonia.(RMPP).
A total of 108 children with refractory mycoplasma pneumoniae pneumonia from June 2018 to October 2020 were randomly divided into two groups: the study group and the control group, with 54 cases in each group. Children in the control group were treated with anti-infective, antitussive, antipyretic routine symptomatic treatment and nebulization of budesonide suspension, while children in the study group were treated with bronchofiberscopic lavage with Budesonide suspension along with standard treatment as in control group. The clinical efficacy, changes in blood gas analysis indexes, levels of inflammatory mediators, time for improvement of clinical symptoms and the incidence of adverse reactions were compared between the two groups.
The efficacy of treatment in the study group was 85.19%, which was higher than 66.67% in the control group (P<0.05). The antipyretic time, antitussive time, lung rales disappearance time and length of hospital stay in the study group were shorter than those in the control group (P<0.05). Moreover, the levels of arterial oxygen partial pressure (PaO) in the study group were higher than those in the control group, while the levels of partial pressure of carbon dioxide (PaCO) and arterial oxygen saturation (SaO) in the study group were lower than those in the control group (P<0.05). The levels of inflammatory mediators interleukin-6 (IL-6), interleukin-4 (IL-4), and interferon-γ (IFN-γ) in the study group were lower than those in the control group (P<0.05), and no significant difference was found in the comparison of the incidence of adverse reactions between the two groups (P>0.05).
Budesonide suspension combined with bronchofiberscopic lavage with Budesonide suspension is a safe treatment regimen that can significantly improve the clinical outcome in children with RMPP. With such a combined treatment regimen, the clinical symptoms of children can be ameliorated, the ventilation function can be enhanced, and the level of inflammatory mediators will be reduced.
探讨布地奈德混悬液经纤维支气管镜灌洗治疗难治性支原体肺炎（RMPP）的临床疗效。
选取2018年6月至2020年10月收治的108例难治性支原体肺炎患儿，随机分为研究组和对照组，每组54例。对照组采用抗感染、止咳、退热等常规对症治疗及布地奈德混悬液雾化吸入，研究组在对照组标准治疗基础上加用布地奈德混悬液纤维支气管镜灌洗。比较两组临床疗效、血气分析指标变化、炎症介质水平、临床症状改善时间及不良反应发生率。
研究组治疗总有效率为85.19%，高于对照组的66.67%（P<0.05）。研究组退热时间、止咳时间、肺部啰音消失时间及住院时间均短于对照组（P<0.05）。此外，研究组动脉血氧分压（PaO）水平高于对照组，二氧化碳分压（PaCO）及动脉血氧饱和度（SaO）水平低于对照组（P<0.
